I like what you said. its makes me wonder exactly where our real need for funding this company will come from.
I am still holding on for now (only small retail investor), but this company has a lot of 'show me please how you expect to succeed' stuff
to do. For example, we will need hundreds of operations data to show to FDA before we can expand into other operative surgical procedural clearance status. <---that will take months and months, and lots of new cash.
But like others have said . . . we are at pivot position in robotic surgery
status of new systems offering to compete against the established mega-company. Lets see what 2018 brings and maybe we do get established pole position in lower-cost robotic surgery market.